Plasma Cell Myeloma Refractory
Plasma Cell Myeloma Refractory is a type of cancer that affects plasma cells in the bone marrow and does not respond to standard treatments, leading to persistent disease despite therapy.
Multiple Myeloma: Isatuximab with Novel Agents
We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years old or older?
- Do you have multiple myeloma (MM) that has come back or not responded to treatment?
- Are you currently taking any medications that could affect your treatment, like blood thinners or steroids?
- Have you had any major health issues in the last 3 months, like a heart attack or stroke?
- Do you have any serious blood problems, like low hemoglobin (less than 8 g/dL) or low platelets (less than 50,000)?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Amelinor
Axium
Cloradex
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Universitaire De Lille
Service des maladies du sang
La Madeleine, France
Assistance Publique Hopitaux De Paris
Service Hematologie adultes
Montrouge, France
Centre Hospitalier Universitaire De Nantes
Service d'Hematologie
Nantes, France
Sponsor: Sanofi-Aventis Recherche & Developpement
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.